{"id":"sofosbuvir-and-daklatasuvir","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sofosbuvir is a nucleotide analog inhibitor that binds to the NS5B RNA-dependent RNA polymerase, preventing viral replication. Daklatasvir is a NS5A inhibitor that binds to the NS5A protein, also preventing viral replication. By inhibiting these two key proteins, the combination of sofosbuvir and daklatasvir is effective in treating hepatitis C virus infection.","oneSentence":"Sofosbuvir and Daklatasuvir work together to inhibit the HCV NS5B RNA-dependent RNA polymerase and NS5A protein, respectively, to treat hepatitis C virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:21.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection"}]},"trialDetails":[{"nctId":"NCT04460443","phase":"PHASE2, PHASE3","title":"Sofosbuvir in Treatment of COVID 19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-08-01","conditions":"COVID","enrollment":60},{"nctId":"NCT04497649","phase":"PHASE2, PHASE3","title":"Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-07-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT03444272","phase":"PHASE3","title":"Effect of Direct-acting Antiviral Drugs on Erectile Function","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":105},{"nctId":"NCT03402165","phase":"PHASE4","title":"Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2017-01-01","conditions":"Hepatitis C","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sofaldy, mpiviropack, daklanork"],"phase":"phase_3","status":"active","brandName":"Sofosbuvir and Daklatasuvir","genericName":"Sofosbuvir and Daklatasuvir","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir is a small molecule inhibitor of RNA-directed RNA polymerase, classified as an INHIBITOR. It has been studied in clinical trials for the treatment of COVID-19, COVID, and Hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}